215 related articles for article (PubMed ID: 32974261)
1. Potential Cost-Savings From the Use of the Biosimilars in Slovakia.
Tesar T; Golias P; Kobliskova Z; Wawruch M; Kawalec P; Inotai A
Front Public Health; 2020; 8():431. PubMed ID: 32974261
[No Abstract] [Full Text] [Related]
2. The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia.
Tesar T; Golias P; Masarykova L; Kawalec P; Inotai A
Front Pharmacol; 2021; 12():795002. PubMed ID: 34966285
[No Abstract] [Full Text] [Related]
3. Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries.
Kawalec P; Stawowczyk E; Tesar T; Skoupa J; Turcu-Stiolica A; Dimitrova M; Petrova GI; Rugaja Z; Männik A; Harsanyi A; Draganic P
Front Pharmacol; 2017; 8():288. PubMed ID: 28642700
[No Abstract] [Full Text] [Related]
4. How Changes in Reimbursement Practices Influence the Financial Sustainability of Medicine Policy: Lessons Learned from Slovakia.
Tesar T; Obsitnik B; Kaló Z; Kristensen FB
Front Pharmacol; 2019; 10():664. PubMed ID: 31249529
[No Abstract] [Full Text] [Related]
5. Cost Burden of Severe Community-Acquired Rotavirus Gastroenteritis Requiring Hospitalization in the Czech Republic, Slovakia, Poland, and Hungary: A Retrospective Patient Chart Review.
Tichopád A; Müllerová J; Jackowska T; Nemes E; Pazdiora P; Sloesen B; Štefkovičová M
Value Health Reg Issues; 2016 Sep; 10():53-60. PubMed ID: 27881278
[TBL] [Abstract][Full Text] [Related]
6. The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
Luukkanen SV; Tolonen HM; Airaksinen M; Saarukka LSM
BioDrugs; 2022 Jul; 36(4):537-547. PubMed ID: 35793041
[TBL] [Abstract][Full Text] [Related]
7. Access to biologicals in Crohn's disease in ten European countries.
Péntek M; Lakatos PL; Oorsprong T; Gulácsi L; Pavlova M; Groot W; Rencz F; Brodszky V; Baji P; Crohn's Disease Research Group
World J Gastroenterol; 2017 Sep; 23(34):6294-6305. PubMed ID: 28974896
[TBL] [Abstract][Full Text] [Related]
8. INTRODUCTION OF HEALTH TECHNOLOGY ASSESSMENT FOR MEDICINES IN SLOVAKIA.
Tesar T; Hloska A; Wawruch M; Lehocka L; Snopkova M; Masarykova L
Int J Technol Assess Health Care; 2017 Jan; 33(3):345-349. PubMed ID: 28434416
[TBL] [Abstract][Full Text] [Related]
9. Reimbursement of biosimilars in Poland: is there a link to health technology assessment?
Neumann D; Jabłecka A
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):781-792. PubMed ID: 26768654
[TBL] [Abstract][Full Text] [Related]
10. Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe.
Malinowski KP; Kawalec P; Trąbka W; Sowada C; Petrova G; Manova M; Savova A; Draganić P; Slabý J; Männik A; Márky K; Rugaja Z; Gulbinovic J; Tesar T; Paveliu MS
Orphanet J Rare Dis; 2020 Oct; 15(1):277. PubMed ID: 33032634
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea.
Lee HJ; Han E; Kim H
Appl Health Econ Health Policy; 2020 Aug; 18(4):557-566. PubMed ID: 31930450
[TBL] [Abstract][Full Text] [Related]
12. Legislative Norms to Control Cannabis Use in the Light of Its Prevalence in Czech Republic, Poland, Slovakia, and Hungary.
Čecho R; Baška T; Švihrová V; Hudečková H
Cent Eur J Public Health; 2017 Dec; 25(4):261-265. PubMed ID: 29346846
[TBL] [Abstract][Full Text] [Related]
13. A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia.
Brodszky V; Rencz F; Péntek M; Baji P; Lakatos PL; Gulácsi L
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):119-25. PubMed ID: 26162458
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab-Polish Experiences.
Barszczewska O; Piechota A
Int J Environ Res Public Health; 2021 Jun; 18(13):. PubMed ID: 34209612
[TBL] [Abstract][Full Text] [Related]
15. Drug Policy in Slovakia.
Bucek Psenkova M; Visnansky M; Mackovicova S; Tomek D
Value Health Reg Issues; 2017 Sep; 13():44-49. PubMed ID: 29073987
[TBL] [Abstract][Full Text] [Related]
16. A health economic guide to market access of biosimilars.
Simoens S; Vulto AG
Expert Opin Biol Ther; 2021 Jan; 21(1):9-17. PubMed ID: 33206021
[No Abstract] [Full Text] [Related]
17. Availability and Accessibility of Orphan Medicinal Products to Patients in Slovakia in the Years 2010-2019.
Foltanova T; Majernik A; Malikova E; Kosirova S
Front Pharmacol; 2022; 13():768325. PubMed ID: 35153774
[No Abstract] [Full Text] [Related]
18. Realization of the EU's Cohesion Policy in Health Care in the Visegrad Group Countries in the Perspective 2014-2020.
Holecki T; Kowalska-Bobko I; Fraczkiewicz-Wronka A; Wegrzyn M
Front Public Health; 2020; 8():133. PubMed ID: 32391306
[TBL] [Abstract][Full Text] [Related]
19. Findings from the Global Youth Tobacco Survey (GYTS) in Czech Republic, Hungary, Poland and Slovakia--smoking initiation, prevalence of tobacco use and cessation.
Baska T; Sovinová H; Nemeth A; Przewozniak K; Warren CW; Kavcová E;
Soz Praventivmed; 2006; 51(2):110-6. PubMed ID: 18027789
[TBL] [Abstract][Full Text] [Related]
20. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Dutta B; Huys I; Vulto AG; Simoens S
BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
